anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: I. Determine which dose of thalidomide (200 mg vs 400 mg) combined with prednisone is the optimally tolerated dose when used as maintenance therapy following autologous stem cell transplantation in patients with multiple myeloma. II. Compare the response rate in patients treated with these regimens. III. Compare the progression-free and overall survival in patients treated with these regimens.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to age (60 and over vs under 60). Within 60-100 days after autologous stem cell transplantation, patients are randomized to 1 of 2 treatment arms. Arm I: Patients receive lower dose oral thalidomide daily and oral prednisone every other day. Arm II: Patients receive higher dose thalidomide daily and oral prednisone every other day. Treatment continues for 2 years in the absence of disease progression or unacceptable toxicity. Patients are followed monthly for 6 months, every 3 months, and then at time of disease progression.

PROJECTED ACCRUAL: A total of 40-80 patients (20-40 per arm) will be accrued for this study within 17-21 months.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes derivative of 2-arylethyl-(piperidine-4-ylmethyl)amine of the formula (I)   wherein R 1  is hydrogen atom, alkoxy-group, alkyl halide comprising in alkyl moiety from 1 to 12 carbon atoms, amino-group; R 2  is alkyl, alkyloxy, alkyl halide comprising in alkyl moiety from 1 to 12 carbon atoms; halogen atom; nitro-group; -O(CH 2 ) p X wherein p = 0; X is taken among alkyl halide comprising from 1 to 12 carbon atom and phenyl;   or R 1  and R 2  in common with ring with which they are bound form 5- or 6-membered monocyclic saturated or unsaturated ring comprising optionally 0, 1 or 2 heteroatoms taken independently of one another among nitrogen, oxygen atom; R 3  and R 4  each means independently of one another a lower alkyl or cycloalkylalkyl comprising from 4 to 14 carbon atoms; R 5  means hydrogen atom;   wherein n = 1-6; R 6  and R 7  each independently means hydrogen atom or lower alkyl, cycloalkyl comprising from 3 to 14 carbon atoms, phenyl or pyridyl; R 9  means alkyl comprising from 1 to 12 carbon atoms; cycloalkyl comprising from 3 to 4 carbon atoms; phenetyl; naphthyl; diphenyl; unsubstituted phenyl or mono-, di- or trisubstituted phenyl wherein its substituents are taken independently among halogen atom; lower alkyl; alkyloxy-group; alkyl halide comprising in alkyl moiety from 1to 12 carbon atoms; cyano-group; nitro-group;   wherein p = 0; X means alkyl halide comprising from 1 to 12 carbon atoms; heterocyclyl representing unsaturated carbocyclic radical comprising 5, 6 ring atoms among them 1 or 2 are taken among nitrogen, oxygen and sulfur atom optionally substituted with one or two substituents among lower alkyl, hydroxy-group, hydroxyalkyl comprising from 1 to 12 carbon atoms, oxo-group, -COR 7  and -COOR 7 ; or heteroaryl representing monocyclic ring comprising one, two or three heteroatoms taken among nitrogen, oxygen, sulfur atom or 9-14-membered bicyclic ring system where one ring is aromatic optionally substituted with lower alkyl and its isomers, racemic mixtures and its pharmaceutically acceptable salts also. Invention describes also a medicinal agent that is an antagonist of muscarine receptor. The proposed compounds can be used for treatment of urogenital system. EFFECT: valuable medicinal properties of compound. 30 cl, 1 tbl, 23 ex
Patients treated with amantadine have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles, which sometimes has resulted in accidents. Patients may not perceive warning signs, such as excessive drowsiness, or they may report feeling alert immediately prior to the event.

Before initiating treatment with OSMOLEX ER, advise patients of the potential to develop drowsiness and specifically ask about factors that may increase the risk for somnolence with OSMOLEX ER, such as concomitant sedating medications, alcohol, or the presence of a sleep disorder. If a patient develops daytime sleepiness or episodes of falling asleep during activities that require full attention (e.g., driving a motor vehicle, conversations, eating), OSMOLEX ER should ordinarily be discontinued.

If a decision is made to continue OSMOLEX ER, advise patients not to drive and to avoid other potentially dangerous activities that might result in harm if they become somnolent. There is insufficient information to establish that dose reduction will eliminate episodes of falling asleep while engaged in activities of daily living or daytime somnolence.
OBJECTIVE: Delirium, an acute confusional state, affects 20-80% of patients in Intensive Care Units (ICUs), one in three medically hospitalized patients, and up to 50% of all patients who have had surgery. Its development is associated with short- and long-term morbidity, and increased risk of death. Yet, we lack any rapid, objective, and automated method to diagnose delirium. Here, we detail the prospective deployment of a novel dual-camera contextual eye-tracking platform. We then use the data from this platform to contemporaneously classify delirium.
RESULTS: We recruited 42 patients, resulting in 210 (114 with delirium, 96 without) recordings of hospitalized patients in ICU across two centers, as part of a prospective multi-center feasibility pilot study. All recordings made with our platform were usable for analysis. We divided the collected data into training and validation cohorts based on the data originating center. We trained two Temporal Convolutional Network (TCN) models that can classify delirium using a pre-existing manual scoring system (Confusion Assessment Method in ICU (CAM-ICU)) as the training target. The first model uses eye movements only which achieves an Area Under the Receiver Operator Curve (AUROC) of 0.67 and a mean Average Precision (mAP) of 0.68. The second model uses the point of regard, the part of the scene the patient is looking at, and increases the AUROC to 0.76 and the mAP to 0.81. These models are the first to classify delirium using continuous non-invasive eye-tracking but will require further clinical prospective validation prior to use as a decision-support tool.
CLINICAL IMPACT: Eye-tracking is a biological signal that can be used to identify delirium in patients in ICU. The platform, alongside the trained neural networks, can automatically, objectively, and continuously classify delirium aiding in the early detection of the deteriorating patient. Future work is aimed at prospective evaluation and clinical translation.
The present invention provides four purified preparation containing a polynucleic acid molecule encoding porcine Torque teno virus (PTTV) genotypes or subtypes PTTV1a-VA, PTTV1b-VA, PTTV2b-VA, and PTTV2c-VA. The present invention also provides infectious DNA clones, biologically functional plasmid or viral vector containing the infectious nucleic acid genome molecule of the same. The present invention further provides live, attenuated, vector-expressed and purified recombinant capsid subunit or killed viral vaccines for protection against PTTV infection. The present invention additionally provides subunit vaccines comprising PTTV specific gene products, especially ORF1 capsid gene product for protection against PTTV infection. Further, the present invention provides methods for diagnosing PTTV infection via polymerase chain reaction (PCR) using specific primer for PTTV1, PTTV2, and individual PTTV1 genotypes. Finally, the present invention provides methods for diagnosing PTTV infection via immunological methods, e.g., enzyme-linked immunoabsorbent assay (ELISA) and Western blot using PTTV specific antigens for detecting serum PTTV specific antibodies.
PROBLEM TO BE SOLVED: To obtain a composite powder having ultraviolet-intercepting effect, suppressed activity, excellent stability and safety and excellent touch in use, by compositing a heat-treated suppressed-activity zinc oxide powder with an inorganic powder and to obtain a cosmetic. SOLUTION: A zinc oxide powder having a mean primary particle diameter of 5nm-100μm, especially 5-100nm itself has strong activity, and therefore its activity is most greatly affected by treatment of lowering activity. Besides, it can be easily composited with an inorganic powder, so that it is particularly desirable. It is spherical, platy, irregular or the like in shape, and its particle size distribution is not particularly limited. This powder is heat-treated by directly heating it to 600-1,700 deg.C for 0.1-48hr or by irradiating it with electromagnetic waves to obtain a suppressed-activity zinc oxide powder. It is also possible that the obtained powder is further subjected to surface treatment such as silicone treatment or silane treatment.  The inorganic powder used is e.g. apatite or hydroxyapatite having a particle diameter of 0.05-100μm and being spherical, platy or the like in shape. This powder is composite with the above obtained suppressed-activity zinc oxide powder in a weight ratio of 1:99 to 99:1.
BACKGROUND: Radical prostatectomy remains the main choice of treatment for prostate cancer. However, despite improvements in surgical techniques and neurovascular sparing procedures, rates of erectile dysfunction, and urinary incontinence remain variable. This is due, at least in part, to an incomplete understanding of neurovascular structures associated with the prostate. The objective of this study was to provide a comprehensive, detailed histological overview of the distribution of nerves and blood vessels within the prostate, facilitating subsequent correlation of prostatic neurovascular structures with patients' clinical outcomes after radical prostatectomy.
METHODS: Neurovascular structures within the prostate were investigated in a total of 309 slides obtained from 15 patients who underwent non-nerve-sparing radical prostatectomy. Immunohistochemical staining was performed to identify and distinguish between parasympathetic and sympathetic nerves, whereas hematoxylin and eosin staining was used to identify blood vessels. The total number, density, and relative position of nerves and blood vessels were established using quantitative morphometry and illustrated using visualization approaches. Patient-specific outcome data were then used to establish whether the internal distribution of nerves and blood vessels within the prostate correlated with the nature and extent of complications after surgery. One-way analysis of variance tests and unpaired t tests were applied to establish statistically significant differences across the measured variables.
RESULTS: Nerves and blood vessels were present across all prostatic levels and regions. However, their number and density varied considerably between regions. Assessment of the precise positioning of neurovascular structures revealed that the majority of nerve fibers were located within the dorsal and peripheral aspects of the gland. In contrast, blood vessels were predominantly located within ventral and dorsal midline regions. The number of intraprostatic nerves was found to be significantly lower in patients who recovered their continence within 12 months of surgery, compared to those whose recovery took 12 months or longer.
CONCLUSION: We report an unexpected disconnect between the localization and positioning of nerve fibers and blood vessels within the prostate. Moreover, individual variability in the density of intraprostatic neurovascular structures appears to correlate with the successful recovery of urinary continence after radical prostatectomy, suggesting that differences in intrinsic neurovascular arrangements of the prostate influence postoperative outcomes.
Patients receive everolimus PO QD and letrozole PO QD. Patients also receive trastuzumab IV over 30-90 minutes once every 3 weeks. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Breast lymphedema is a common sequela of breast conservation that delays healing and reduces quality of life. No rigorous classification system exists for this condition. We explored approaches for classifying breast lymph-edema based on breast ultrasound, physical exam, and patient-reported outcomes. We enrolled 80 patients from two institutions. Each site enrolled 30 invasive breast cancer patients treated with breast conservation and radiotherapy, and 10 control patients evaluated for benign breast complaints. All patients underwent bilateral breast ultrasound to measure dermal thickness and were assessed for physical signs of breast lymphedema. Patients reported quality of life impacts on standard questionnaires. We derived breast lymphedema classifiers using (1) a simple ultrasound-based metric of dermal thickness difference, and (2) a multiparameter machine learning classifier based on dermal thickness difference, physical exam, and patient-reported impacts. Ultrasound-defined breast lymphedema was present in 72% (95% CI: 59 to 82%) of invasive breast cancer patients. The multiparameter classifier identified three distinct patient groups: one with little evidence of breast lymph-edema, and two with increasingly severe breast lymphedema. A simple ultrasound-based measure and a novel multiparameter classifier both show promise for rigorous classification of breast lymphedema and warrant further development in larger patient cohorts.
Obesity has emerged as a worldwide health concern due to its increasing prevalence. Adipocytes have the ability to express angiotensin-converting enzyme 2 receptors (ACE2) and several adipocytokines. These expressions could lead to the activation of a cytokine storm, which in turn promotes the development of cardiovascular diseases. The aim of this study was to investigate the impact of perindopril and losartan exposure on the ACE2 and interleukin 6 (IL-6) levels in adipocyte cells. This study used an in vivo true experimental design utilizing a post-test-only control group. A total of 24 adult male albino rats were divided into four groups, one group served as the non-obese (negative control), while the other three groups were obese: (1) the positive control (untreated obese rats); (2) perindopril group (2 mg/kg BW/day orally for 4 weeks); and (3) losartan group (20 mg/kg BW/day for 4 weeks). Afterwards, the rats were euthanized, and the visceral fat tissue were obtained during dissection. The levels of ACE2 and IL-6 were measured using the enzyme-linked immunosorbent assay (ELISA). Losartan administration in obese rats resulted in a notable elevation in ACE2 levels compared to both the perindopril group (losartan vs perindopril, p=0.011) and the positive control (p=0.004). In addition, the treatment of perindopril and losartan in obese rats resulted in a significant reduction in IL-6 levels when compared to the positive control (perindopril vs positive control, p=0.020; losartan vs positive control, p=0.002, respectively). This study provides insight into the administration of perindopril and losartan, which could suppress the pro-inflammatory (IL-6) but increase the ACE2 levels in adipose tissue.
Mother's Own Milk (MOM) is recommended for preterm babies. However, on average, mothers giving birth preterm are able to provide less than half their baby's milk requirements. Standard clinical practice is to make up any shortfall in MOM with either pasteurised Human Donor Milk (HDM) or Preterm Formula (PTF). Which option is more beneficial to clinical outcomes is unknown.

Pasteurisation reduces or destroys many biologically active components and HDM, unlike PTF, is very variable in composition. Clinicians who use HDM do so primarily in the hope that despite pasteurisation it will reduce bloodstream infection and necrotising enterocolitis, a serious, devastating inflammatory disease characterised by bowel death and multisystem failure. These are two of the most feared conditions in newborn medicine as described above. Landmark nutritional trials in the early 1980's suggest positive effects of human milk on insulin sensitivity, and other metabolic outcomes. Clinicians who prefer PTF believe it benefits growth, including brain growth, and improves neurodevelopmental outcome.

Neonates born below 32 weeks gestational age will be randomised to receive fortified HDM, unfortified HDM, or PTF to make up any shortfall in MOM until 35 weeks postmenstrual age with a sample size of 22 in each group. The trial is designed to reflect current preterm feeding practice. The trial will take place in neonatal units in London and parent consent obtained within 48hr of birth. Permission will be sought for long term follow up, initially from parents (later from children themselves). Outcomes will be body composition using magnetic resonance imaging and other imaging techniques. This pilot study will specifically assess feasibility by testing 1) provision of HDM by Human Milk Banks in London 2) acceptability to parents and clinicians using feedback on trial design 3) recruitment to target and 4) retrieval of clinical data for all recruited babies form the National Neonatal Database.
Investigators will compare self-confidence and competence scores between the three groups after the pre-test and posttest simulations. The self-efficacy survey is an 7-item scale that involves participants rating their self-efficacy about providing care for multiple patients. Participants rate their self-efficacy on a 1 to 5 (not confident to very confident scale). The survey takes 5 minutes to complete. The self-efficacy survey has been used in many simulation research studies previously with novice nurses. Competence will be measured with a rater-observation measure which has previously been used in simulation research.
<P>PROBLEM TO BE SOLVED: To provide a method for searching a combination of inhibitors for efficiently inhibiting generation of a plurality of products (an intermediate product and a final product) in an identical or different Maillard reaction.  <P>SOLUTION: In the method for searching the inhibitors of the Maillard reaction, the combination of the first inhibitor and the second inhibitor is searched. The first inhibitor inhibits a reaction for generating one first product or more selected from a product group including the intermediate product generated during a reaction process and the final product in the Maillard reaction. The second inhibitor inhibits a reaction for generating one second product or more selected from the product group. The method specifies the first and second products, examines an activity for inhibiting the first and second products of a plurality of inhibited candidate materials, and preferably determines the combination of the first and second inhibitors.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Total of 24 cycles of lenalidomide. Subjects received a starting daily dose of 10mg lenalidomide on days 1 through 28 of each 28 day cycle. Subjects initiated lenalidomide 28-100 days post-ASCT.
LOU064 placebo (blinded) taken orally for 24 weeks, followed by LOU064 (open-label) taken orally for 28 weeks. Randomized in a 2:1 ratio (arm 1:arm 2).
A system for providing improved processing of data collected during a clinical trial. The system includes a portable electronic device configured to be operated by a clinician and/or a patient. The portable electronic device is configured for collecting data related to the condition of the patient participating in the clinical trial. The system also includes a controller for processing data collected from the patient. The data received from the patient includes AV data, bio sensor data, and clinician data based on information inputted into the portable electronic device by the clinician in response to an interview of the patient. The controller is configured to process the AV, bio data sensor and clinician data and output a recommended course of action related to the patient's participation in the clinical trial based on the data received from the patient.
An invention that adduces cogent evidence to establish that oxygenated dibenzo-α-pyrones (DBPs and their conjugates), the major bioactives of shilajit (Ayurvedic vitalizer), have their origin, at least partly, in EPA and DHA. Earlier research has shown that, in mammals, C-20 PUFAs are metabolized by oxygenases and other enzymes to produce short-lived prostaglandins, leukotrienes and thromboxanes that bind to specific G-protein-coupled receptors and signal cellular responses, e.g., inflammation, vasodilation, blood pressure, pain etc. But never before it was suggested/shown that C20:5n-3 PUFAs, e.g., EPA (and DHA), are transformed into stable aromatic metabolites, DBPs, which elicit a large array of bioactivities in the producer organisms and also control the synthesis and metabolism of arachidonate-derived prostaglandins. The major beneficial effects attributed to EPA and DHA are now found to be largely contributed by DBPs and their aminoacyl conjugates and the dibenzo-α-pyrone-chromoproteins (DCPs). Because of the highly unstable nature of EPA and DHA, when administered, they are metabolized into a large array of uncontrolled products, several of which are systemically undesirable. By contrast, DBPs, because of their stability, perform the biological response modifier (BRM) functions in a directed and sustained way. Many of the biological effects of DBPs described in this invention, were earlier attributed to EPA and DHA, - the precursors of DBPs.
Patients complete at least 30 minutes of moderate intensity aerobic exercise (such as brisk walking or stationary bike cycling) at least 3 times per week. Patients also complete strength exercises with resistance tubes/bands at least 2 times per week, with at least 2 sets of 8-15 repetitions of the exercises taught. Patients receive nutrition consultation with a registered dietitian and monitor dietary intake. Patients also consume a high protein snack/meal/shake (15-25 grams) within 1 hour after any strengthening exercises. Exercise activities and nutrition are tracked in the Pt Pal app.
We report a fetus with prenatal ultrasound at 21 gestational weeks showing left cystic renal dysplasia with subcapsular cysts and echogenic parenchyma, right echogenic kidney with absent corticomedullary differentiation, and left congenital diaphragmatic hernia (CDH) with bowel herniation, with intestinal atresia (IA) found on postmortem examination. Whole genome sequencing of fetal blood DNA revealed a heterozygous pathogenic variant c.344 + 2 T>G in the HNF1B gene (NM_000458). Sanger sequencing of the parental samples suggested that it arose de novo in the fetus. HNF1B-associated disorders affect multiple organs with significant phenotypic heterogeneity. In pediatric and adult patients, renal cystic disease and cystic dysplasia are the dominant phenotypes. In prenatal settings, renal anomaly is also the most common presentation, typically with bilateral hyperechogenic kidneys. Our case presented with two uncommon extra-renal phenotypes of CDH and IA besides the typical bilateral cystic renal dysplasia. This association has been reported in fetuses with 17q12 microdeletion but not with HNF1B point mutation. Our case is the first prenatal report of such an association and highlights the possible causal relationship of HNF1B defects with CDH and IA in addition to the typical renal anomalies.
Previous studies have suggested that nut consumption imparts a variety of health benefits, including reduction of cardiovascular disease and improved satiety. However, studies of pistachios are extremely limited. The aim of this study is to determine the energy value of pistachios in the human diet and to probe mechanisms by which pistachios impart health benefits. The metabolizable energy value of pistachio nuts will be calculated based on the chemical composition and energy content of the consumed diet and excreta. This will provide a better estimate of the energy value of pistachios than simply calculating energy value based on Atwater factors. In addition to determining the energy value of pistachios, we will evaluate the effects of pistachio-rich diets on plasma phytonutrient levels and on gene expression changes to determine what protective mechanisms are activated by pistachio consumption.